You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
再鼎醫藥-SB(09688.HK)一季度總收入上升至4670萬美元

格隆匯5月11日丨再鼎醫藥-SB(09688.HK)發佈2022年第一季度財務業績公吿,截至2022年3月31日止三個月,總收入為4,670萬美元,2021年同期收入為2,010萬美元。其中包括則樂產品銷售收入2,960萬美元(2021年同期為1,260萬美元)、愛普盾產品銷售收入1,280萬美元(2021年同期為710萬美元)、擎樂產品銷售收入300萬美元(2021年同期為40萬美元)、紐再樂產品銷售收入70萬美元(2021年同期無收入)。

截至2022年3月31日止三個月,研究與開發(研發)支出為5,390萬美元,2021年同期為2.039億美元。研發開支的降低主要由於沒有新的授權引進預付款,部分被正在進行及新啟動的後期臨牀研究的相關費用、增聘研發人員的工資及工資相關開支抵銷。不計入新的授權引進預付款,期內核心研發開支為5,390萬美元,2021年同期為4,160萬美元。截至2022年3月31日止三個月,再鼎醫藥虧損淨額為8,240萬美元,2021年同期的虧損淨額為2.329億美元。虧損淨額的減少主要由於沒有新的授權引進預付款。期內每股普通股淨虧損為0.09美元,而2021年同期為0.26美元。期內每股ADS淨虧損為0.86美元,而2021年同期為2.64美元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account